Shubham Pant, MD

Articles

Expert Insights: Challenges With ctDNA Testing in BTC

February 26th 2025

Panelists discuss how circulating tumor DNA (ctDNA) testing in biliary tract cancer (BTC) presents unique technical and interpretative challenges, including considerations around sensitivity, timing of collection, and clinical validation of results.

Biomarker Testing in BTC: Approaches and Practices Across Academic and Community Clinicians

February 26th 2025

Panelists discuss how clinicians are increasingly utilizing both tissue and liquid biopsies with comprehensive DNA/RNA next-generation sequencing (NGS) for biomarker testing in biliary tract cancer (BTC), while noting variations in testing practices across different treatment centers.

The Importance of Early Biomarker Testing in Managing Advanced BTC

February 19th 2025

Panelists discuss how comprehensive molecular profiling and biomarker testing are critical for guiding targeted therapy decisions in advanced biliary tract cancer (BTC), citing recent real-world data presented at ASCO GI that demonstrated improved outcomes with matched targeted therapies.

Guiding Patients Through Advanced BTC Prognosis and Expectations

February 19th 2025

Panelists discuss how physicians typically communicate survival outcomes and prognosis to patients with newly diagnosed advanced biliary tract cancer (BTC), focusing on setting realistic expectations while maintaining hope.

Dr Pant on the Importance of Targeted Therapy and Mutation Testing in Pancreatic Cancer

November 22nd 2024

Shubham Pant, MD, MBBS, discusses next-generation sequencing in pancreatic cancer, highlighting the importance of targeting RAS mutations when applicable.

Dr Pant on the Utility of Zanidatamab in Previously Treated HER2+ Biliary Tract Cancer

June 20th 2024

Shubham Pant, MD, MBBS, discusses the utility of zanidatamab in patients with previously treated HER2+ biliary tract cancer.

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

May 23rd 2024

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

Dr Pant on the Background of the RAGNAR Trial in FGFR-altered Solid Tumors

June 28th 2023

Shubham Pant, MD, MBBS, discusses the background of the ongoing phase 2 RAGNAR trial evaluating the use of erdafitinib in patients with solid tumors harboring FGFR alterations.

Dr Pant on the Investigation of Adagrasib in KRAS G12C–Mutated Solid Tumors

June 21st 2023

Shubham Pant, MD, MBBS, discusses the investigation of adagrasib in the treatment of patients with KRAS G12C–mutated advanced solid tumors.

Dr Pant on the Investigation of Zanidatamab in Biliary Tract Cancer

June 9th 2023

Shubham Pant, MD, MBBS, discusses the rationale for the phase 2b HERIZON-BTC-01 trial and shares the results with zanidatamab in previously treated HER2-amplified biliary tract cancer.

Dr. Pant on the RAGNAR Trial of Erdafitinib in Biliary Tract Cancer

January 26th 2023

Shubham Pant, MD, discusses the rationale, trial design, and key efficacy and safety data from an expansion cohort of the phase 2 RAGNAR trial in biliary tract cancers.

Dr. Pant on the Role of Genetic Testing in Pancreatic Cancer

October 29th 2020

Shubham Pant, MD, discusses the role of genetic testing in pancreatic cancer.

Dr. Pant on Targeting KRAS Mutations in Metastatic Solid Tumors

August 27th 2020

Shubham Pant, MD, discusses targeting KRAS mutations in advanced or metastatic solid tumors.

Dr. Pant on Choosing Therapy for Frontline and Beyond in Pancreatic Cancer

April 3rd 2020

Shubham Pant, MD, discusses choosing therapy for the frontline and beyond in pancreatic cancer.

Dr. Pant on Exciting Data With PARP Inhibitors in Pancreatic Cancer

March 13th 2020

Shubham Pant, MD, discusses exciting data with PARP inhibitors in pancreatic cancer.

Dr. Pant on Immunotherapy Combos and Upcoming Developments in Pancreatic Cancer

March 10th 2020

Shubham Pant, MD, discusses combination immunotherapies and upcoming developments in pancreatic cancer.

Dr. Pant on the Future of mCRC Treatment

March 28th 2018

Shubham Pant, MD, associate medical director of the Clinical & Translational Research Center, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing efforts in metastatic colorectal cancer (mCRC) and his hope for the future treatment landscape.

Dr. Pant on the Third-Line Setting for Metastatic CRC

December 6th 2017

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the third-line setting for patients with metastatic colorectal cancer (CRC).

Dr. Pant Discusses the Current Treatment Landscape of CRC

November 22nd 2017

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the current treatment landscape of colorectal cancer.